

# A Comparison of Pharmacokinetic and Pharmacodynamic Insulin Aspart and Insulin Aspart in Elderly Subjects with

Drugs and Aging

34, 29-38

DOI: [10.1007/s40266-016-0418-6](https://doi.org/10.1007/s40266-016-0418-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. <i>Clinical Pharmacokinetics</i> , 2017, 56, 551-559.	1.6	150
2	Insulin analogues in type 1 diabetes mellitus: getting better all the time. <i>Nature Reviews Endocrinology</i> , 2017, 13, 385-399.	4.3	170
3	Development of glucose-responsive "smart" insulin systems. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 267-278.	1.2	47
4	Pharmacological Properties of Faster-Acting Insulin Aspart. <i>Current Diabetes Reports</i> , 2017, 17, 101.	1.7	20
7	Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2019, 58, 421-430.	1.6	19
8	Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. <i>Diabetes Therapy</i> , 2019, 10, 1793-1800.	1.2	11
9	Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2039-2047.	2.2	41
10	Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2068-2075.	2.2	15
11	Pharmacologic treatment options for type 1 diabetes: what's new?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 471-479.	1.3	13
12	Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. <i>Canadian Journal of Diabetes</i> , 2019, 43, 515-523.	0.4	32
13	Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2019, 58, 639-649.	1.6	8
14	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. <i>Clinical Pharmacokinetics</i> , 2020, 59, 155-172.	1.6	35
15	Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 and Diabetes Mellitus: A Practical Approach. <i>Diabetes Therapy</i> , 2020, 11, 2177-2194.	1.2	16
16	Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 448-455.	4.3	18
17	Si l'ère des insulines semi-synthétiques et biosynthétiques nous attendait. <i>Medecine Des Maladies Metaboliques</i> , 2021, 15, 3S32-3S52.	0.1	1
18	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1789-1798.	2.2	49
19	Thérapeutique des désordres glycémiques. , 2019, , 141-252.		0
20	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. <i>Diabetes Mellitus</i> , 2020, 23, 140-160.	0.5	0

#	ARTICLE	IF	CITATIONS
21	Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2021, , 1.	1.6	5
22	Opportunities and Challenges for Nanotherapeutics for the Aging Population. <i>Frontiers in Nanotechnology</i> , 2022, 4, .	2.4	8
23	Acute diabetes complications. <i>Journal of Gerontology and Geriatrics</i> , 2021, 69, 269-275.	0.2	0
24	<scp>Rapidâ€œacting</scp> insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 63-74.	2.2	4
25	Evaluation of the Pharmacokinetic Profile of Ultra Rapid Lispro Administered Subcutaneously at Different Injection Sites. <i>Clinical Therapeutics</i> , 2022, , .	1.1	0